Advertisement

European Journal of Clinical Pharmacology

, Volume 12, Issue 2, pp 125–132 | Cite as

Disposition of valproic acid in man

  • R. Gugler
  • A. Schell
  • M. Eichelbaum
  • W. Fröscher
  • H. -U. Schulz
Originals

Summary

The pharmacokinetics of valproic acid (VPA) have been studied in 6 healthy subjects following a single 600 mg dose, and after multiple doses over 12 days (1200 mg daily) of enteric-coated sodium valproate. A time lag before absorption of 1 to 2 h was observed in each subject, and then absorption was rapid, peak concentrations being recorded 3 to 4 h after administration of the dose. The plasma level decline was biphasic with a terminal half-life of 15.9±2.6 h in the single dose and 17.3±3.0 h in the multiple dose experiments. There was no evidence of dose dependent kinetics or autoinduction. Total plasma clearance was 0.0064±0.0011 l/kg×h. The apparent volume of distribution was small at 0.15±0.2 l/kg. The mean steady state plasma concentration (Css) reached after 4 days was 81.3±13.0 µg/ml. Css observed was lower than Css predicted (99.2±14.7 µg/ml) from single dose kinetics (p<0.001). The difference was probably due to a reduction in plasma protein binding at higher concentrations. VPA concentration in saliva was between 0.4 and 4.5% of the total plasma concentration and was not equal to the concentration of unbound drug in plasma (6.7±0.8% unbound). 3.2% of the dose was excreted in urine as the parent drug and 21.2% as conjugated metabolites.

Key words

Valproic acid pharmacokinetics saliva concentration urinary excretion serum protein binding 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Arnold, K., Gerber, N.: The rate of decline of diphenylhydantoin in human plasma. Clin. Pharmacol. Ther.11, 121–134 (1970)Google Scholar
  2. Bergamini, L., Mutani, R., Furlan, P.M., Riccio, A.: Le Dépakine dans le traitement de l'épilepsie essentielle ou idiopathique. Arch. Suisse Neurol. Neurochir. Psychiat.106, 1–7 (1970)Google Scholar
  3. Bochner, F., Hooper, W.D., Sutherland, J.M., Eadie, M.I., Tyrer, J.H.: Diphenylhydantoin concentrations in saliva. Arch. Neurol. (Chic.)31, 57–59 (1974)Google Scholar
  4. Burton, B.S.: On the propyl derivatives and decomposition products of ethyl acetoacetate. Amer. chem. J.3, 385–395 (1881)Google Scholar
  5. Eichelbaum, M., Ekbom, K., Ringberger, V.A., Bertilsson L., Rane, A.: Plasma kinetics of carbamazepine and its epoxide metabolite in man during single and multiple dosing. Europ. J. Clin. Pharmacol.8, 337–341 (1975)Google Scholar
  6. Ferrandez, B., Eymard, P.: Méthode rapide d'analyse quantitative du dipropylacétate de sodium dans le sérum ou le plasma. Ann. Pharm. Fr.31, 279–282 (1973)Google Scholar
  7. Gugler, R., Shoeman, D.W., Huffman, D.H., Cohlmia, J.B., Azarnoff, D.L.: Pharmacokinetics of drugs in patients with the nephrotic syndrome. J. clin. Invest.55, 1182–1189 (1975)Google Scholar
  8. Gugler, R., Mueller, G.: Plasma protein binding of valproic acid in healthy subjects and in patients with renal disease. Brit. J. clin. Pharmacol., in pressGoogle Scholar
  9. Hartlapp, J.H., Gugler, R.: Single versus multiple dose pharmacokinetics of clofibrate. Naunyn Schmiedeberg's Arch. Pharmacol.293 Suppl., R 63 (1976)Google Scholar
  10. Jensen, C.J., Gugler, R.: A sensitive GLC method for determination of valproic acid in biological fluids. J. Chromatogr.137, 188–193 (1977)Google Scholar
  11. Klotz, U., Antonin, K.H.: Pharmacokinetics and bioavailability sodium valproate. Clin. Pharmacol. Ther.21, 736–743 (1977)Google Scholar
  12. Loiseau, P., Brachet, A. and Henry, P.: Concentration of dipropylacetate in plasma. Epilepsia16, 609–615 (1975)Google Scholar
  13. Matin, S.B., Wan, S.H., Karam, J.H.: Pharmacokinetics of tolbutamide: Prediction by concentration in saliva. Clin. Pharmacol. Ther.16, 1052–1058 (1974)Google Scholar
  14. Meinardi, H.: Clinical trials of antiepileptic drugs. Psychiat. Neurol. Neurochir.74, 435–483 (1971)Google Scholar
  15. Meunier, H., Carraz, G., Meunier, V., Eymard, M.: Propriétés pharmacodynamiques de l'acide n-propylacétique. Thérapie18, 435–438 (1963)Google Scholar
  16. Reidenberg, M.M., Odar-Cederlöf, I., von Bahr, C., Borgå, O., Sjöqvist, F.: Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function. N. Engl. J. Med.285, 264–267 (1971)Google Scholar
  17. Remmer, H., Siegert, M.: Kumulation und Elimination von Phenobarbital. Naunyn Schmiedeberg's Arch. Pharmakol.243, 479–494 (1962)Google Scholar
  18. Richens, A., Ahmad, S.: Controlled trial of sodium valproite in severe epilepsy. Brit. med. J.4, 255–256 (1975)Google Scholar
  19. Simon, D., Penry, J.K.: Sodium di-n-propylacetate (DPA) in the treatment of epilepsy. Epilepsia16, 549–573 (1975)Google Scholar
  20. Sonnen, A.E.H., Blom, G.F., Meijer, J.W.A.: Enteric coated dipropylacetate (Depakine). Clinical Pharmacology of Antiepileptic Drugs. (ed. Schneider, H., Janz, D., Gardner-Thorpe, C., Meinardi, H., Sherwin, A.L., pp. 229–234. Berlin, Heidelberg, New York: Springer-Verlag 1975Google Scholar
  21. Suzuki, M., Marujama, H., Ishibashi, Y., Ogawa, S., Seki, T., Hoshino, M., Maekawa, K., Yo, T., Sato, Y.: Double blind comparative trial of sodium dipropylacetate and ethosuximide in epilepsy in children. The special emphasis on pure petit mal seizure. (Japan.) Med. Prog.82, 470–488 (1972)Google Scholar
  22. Troupin, A. S., Friel, P.: Anticonvulsant level in saliva, serum and cerebrospinal fluid. Epilepsia16, 223–227 (1975)Google Scholar
  23. Wagner, J.G., Northam, J.I., Alway, C.D., Carpenter, O.S.: Blood levels of drugs at equilibrium state after multiple dosing. Nature207, 1301–1302 (1965)Google Scholar
  24. Wallace, S., Brodie, M.J.: Decreased drug binding in patients with chronic hepatic disease. Europ. J. Clin. Pharmacol.9, 429–432 (1976)Google Scholar

Copyright information

© Springer-Verlag 1977

Authors and Affiliations

  • R. Gugler
    • 1
  • A. Schell
    • 1
  • M. Eichelbaum
    • 1
  • W. Fröscher
    • 1
  • H. -U. Schulz
    • 1
  1. 1.Departments of Medicine and NeurologyUniversity of BonnBonnGermany

Personalised recommendations